This drug could halve death risk from most common type of lung cancer


By AGENCY
An already-available drug shows evidence of helping to increase the survival rate in patients with EGRF mutations of non-small cell lung cancer. — AFP

A pill has been shown to halve the risk of death from a certain type of lung cancer when taken daily after surgery to remove the tumour, according to clinical trial results presented on June 4 (2023).

The results were unveiled in Chicago, United States, at the largest annual conference of cancer specialists, hosted by the American Society for Clinical Oncology (ASCO).

Play, subscribe and stand a chance to win prizes worth over RM39,000! T&C applies.

Monthly Plan

RM 13.90/month

RM 11.12/month

Billed as RM 11.12 for the 1st month, RM 13.90 thereafter.

Best Value

Annual Plan

RM 12.33/month

RM 9.87/month

Billed as RM 118.40 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!
Lung cancer , drugs , cancer

Next In Health

Try these golf exercises to enhance your game
What you could be eating in future is changing rapidly
Oncologist: ‘There was no space to feel’
Don't believe everything chatbots�tell you
The trigger behind gut scarring in Crohn’s disease
Daily habits to help prevent dementia�
Cultivating resilience in our children�
We need to remove barriers to physical activity�
Mental health check�for the family
Sugar to soothe the pain�for hospitalised newborns

Others Also Read